About Meitheal
In 2017, we set out to bridge important gaps in the market. Namely, the need for:
Generic injectables. We made significant investments in generics, and continue to do so, when other producers are scaling back. Because where they have growing priorities elsewhere, we see an even bigger need for a reliable supply of these life sustaining drugs.
Simplicity. Healthcare is difficult enough. So if we’re going to work hard at anything, it’s at being uncomplicated, accountable – and doing so with integrity, transparency and speed.